Literature DB >> 10376970

Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours.

G Nawa1, Y Miyoshi, H Yoshikawa, T Ochi, Y Nakamura.   

Abstract

We investigated expression of a human p53-inducible gene, P2XM, a member of the P2X-receptor family of ATP-gated ion channels, in 56 human primary soft-tissue tumours including 47 sarcomas and nine benign tumors. Among the 47 sarcomas examined by reverse transcription polymerase chain reaction, 12 had lost expression of this gene and 22 revealed altered splicing patterns; among the nine benign tumours, four showed no expression of P2XM and three revealed aberrant splicing patterns involving transmembrane domains M1 and/or M2. As the aberrant transcripts lacked either or both of those domains, the protein products probably lacked normal function. We also looked for p53 mutations and mdm2 overexpression in the same panel of tumours and found them in 13 tumours, all but three of which had shown altered expression of P2XM. However, 31 (72%) of the 43 tumours that carried wild-type p53 without mdm2 overexpression had revealed aberrant P2XM expression. Our results suggest that disorder of P2XM expression may play a crucial role in the genesis of benign and malignant tumours in soft tissues, and that one or more genetic factors other than p53 or mdm2 contribute significantly to aberrant P2XM expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376970      PMCID: PMC2362367          DOI: 10.1038/sj.bjc.6690484

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

1.  Detection of TP53 gene mutations in human sarcomas.

Authors:  J S Castresana; M P Rubio; L Gómez; A Kreicbergs; A Zetterberg; C Barrios
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

2.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

3.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

4.  The p53-mdm-2 autoregulatory feedback loop.

Authors:  X Wu; J H Bayle; D Olson; A J Levine
Journal:  Genes Dev       Date:  1993-07       Impact factor: 11.361

5.  Cloning of P2XM, a novel human P2X receptor gene regulated by p53.

Authors:  T Urano; H Nishimori; H Han; T Furuhata; Y Kimura; Y Nakamura; T Tokino
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

6.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.

Authors:  C Cordon-Cardo; E Latres; M Drobnjak; M R Oliva; D Pollack; J M Woodruff; V Marechal; J Chen; M F Brennan; A J Levine
Journal:  Cancer Res       Date:  1994-02-01       Impact factor: 12.701

7.  Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas.

Authors:  E Latres; M Drobnjak; D Pollack; M R Oliva; M Ramos; M Karpeh; J M Woodruff; C Cordon-Cardo
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

8.  p53 abnormalities in different subtypes of human sarcomas.

Authors:  A Andreassen; T Oyjord; E Hovig; R Holm; V A Flørenes; J M Nesland; O Myklebost; J Høie; O S Bruland; A L Børresen
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

9.  No association between c-myc amplification and TP53 mutation in sarcoma tumorigenesis.

Authors:  J S Castresana; C Barrios; L Gómez; A Kreicbergs
Journal:  Cancer Genet Cytogenet       Date:  1994-08

10.  Cyclin G is a transcriptional target of the p53 tumor suppressor protein.

Authors:  K Okamoto; D Beach
Journal:  EMBO J       Date:  1994-10-17       Impact factor: 11.598

View more
  6 in total

Review 1.  Molecular and functional properties of P2X receptors--recent progress and persisting challenges.

Authors:  Karina Kaczmarek-Hájek; Eva Lörinczi; Ralf Hausmann; Annette Nicke
Journal:  Purinergic Signal       Date:  2012-05-01       Impact factor: 3.765

Review 2.  Determination of the architecture of ionotropic receptors using AFM imaging.

Authors:  Nelson P Barrera; Robert M Henderson; J Michael Edwardson
Journal:  Pflugers Arch       Date:  2007-11-17       Impact factor: 3.657

3.  Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.

Authors:  Danielle C Shing; Maurizio Trubia; Francesco Marchesi; Enrico Radaelli; Elena Belloni; Cinzia Tapinassi; Eugenio Scanziani; Cristina Mecucci; Barbara Crescenzi; Idoya Lahortiga; Maria D Odero; Giuseppe Zardo; Alicja Gruszka; Saverio Minucci; Pier Paolo Di Fiore; Pier Giuseppe Pelicci
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

4.  The stoichiometry of P2X2/6 receptor heteromers depends on relative subunit expression levels.

Authors:  Nelson P Barrera; Robert M Henderson; Ruth D Murrell-Lagnado; J Michael Edwardson
Journal:  Biophys J       Date:  2007-04-20       Impact factor: 4.033

5.  Targeting the p53 Pathway in Ewing Sarcoma.

Authors:  Paul M Neilsen; Kathleen I Pishas; David F Callen; David M Thomas
Journal:  Sarcoma       Date:  2010-12-09

6.  Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma.

Authors:  Simona Ognjanovic; Ghyslaine Martel; Carlos Manivel; Magali Olivier; Erica Langer; Pierre Hainaut
Journal:  Sarcoma       Date:  2012-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.